Quantitative immunohistochemistry analysis of pancreatic adenocarcinoma upregulated factor expression in pancreatic cancer and its prognostic significance

Table 4 Multivariate analysis of prognostic factors including high and low expression of pancreatic adenocarcinoma upregulated factor (high vs low)

Factors	Overall survival, hazard ratio (95% confidence interval)	P value
PAUF expression, high vs low	2.05 (1.19-3.53)	0.009b
Age	1.01 (0.98-1.03)	0.921
Location
Head	Reference
Body	1.85 (0.94-3.66)	0.076
Tail	1.02 (0.53-1.96)	0.959
Stage
RPC	Reference
BRPC	1.07 (0.61-1.89)	0.813
Histology
WD or MD	Reference
PD	2.47 (1.34-4.58)	0.004b
RM
Negative	Reference
Positive	1.00 (0.58-1.72)	0.998
Nodal status
Negative	Reference
Positive	1.24 (0.69-2.25)	0.472
Adjuvant therapy	0.39 (0.24-0.64)	0.001b
CA19-9 (< 150 vs ≥ 150 U/mL)	1.12 (0.68-1.58)	0.65

^bP < 0.01 vs pancreatic adenocarcinoma upregulated factor-low group, well/moderately differentiated tumors, and no adjuvant therapy.

PAUF: Pancreatic adenocarcinoma upregulated factor; RPC: Resectable pancreatic cancer; BRPC: Borderline resectable pancreatic cancer; RM: Resection margin; CA 19-9: Carbohydrate antigen 19-9; PD: Poorly differentiated; WD: Well differentiated; MD: Moderately differentiated.